SCHEMBL5376186

SCHEMBL5376186

FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CCBr

nearest known ligand 0.41

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9854257 1.00 LMNA (0.41) LMNA
SCHEMBL5556024 1.00 LMNA (0.41) LMNA
SCHEMBL9854413 1.00 LMNA (0.41) LMNA
SCHEMBL9854339 1.00 LMNA (0.41) LMNA
SCHEMBL2495980 0.97 LMNA (0.36) LMNA
SCHEMBL9854322 0.88 LMNA (0.32) LMNA
SCHEMBL29461640 0.88
SCHEMBL3480962 0.84 LMNA (0.38) LMNA
SCHEMBL28070551 0.82 LMNA (0.36) LMNA
SCHEMBL7643011 0.82 LMNA (0.42) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739728-A1 TUNABLE POLYISOBUTYLENE POLYURETHANE Boston Scientific Scimed, Inc. (US) 2026-05-13 EP claimed
WO-2025010284-A1 TUNABLE POLYISOBUTYLENE POLYURETHANE BOSTON SCIENTIFIC SCIMED INC. (US) 2025-01-09 WO claimed
US-20250011541-A1 TUNABLE POLYISOBUTYLENE POLYURETHANE BOSTON SCIENTIFIC SCIMED, INC. 2025-01-09 US claimed
EP-4739728-A1 TUNABLE POLYISOBUTYLENE POLYURETHANE Boston Scientific Scimed, Inc. (US) 2026-05-13 EP disclosed
WO-2025010284-A1 TUNABLE POLYISOBUTYLENE POLYURETHANE BOSTON SCIENTIFIC SCIMED INC. (US) 2025-01-09 WO disclosed
US-20250011541-A1 TUNABLE POLYISOBUTYLENE POLYURETHANE BOSTON SCIENTIFIC SCIMED, INC. 2025-01-09 US disclosed
CN-111501409-A Suspension for deacidifying paper 齐鲁工业大学 2020-08-07 CN disclosed
US-7226578-B2 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SHERING AG (DE) 2007-06-05 US disclosed
US-6916461-B2 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SCHERING AG (DE) 2005-07-12 US disclosed
US-20050147563-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-07 US disclosed
US-20030232012-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SCHERING AG (DE) 2003-12-18 US disclosed
US-6468502-B1 PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA SCHERING AKTIENGESELLSCHAFT (DE) 2002-10-22 US disclosed
EP-0874645-B1 PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS SCHERING AG (DE) 2002-04-03 EP disclosed
EP-0882010-B1 PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY SCHERING AG (DE) 2001-05-02 EP disclosed
US-6180113-B1 USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY SCHERING AG (DE) 2001-01-30 US disclosed
EP-0882010-A1 PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY SCHERING AKTIENGESELLSCHAFT (DE) 1998-12-09 EP disclosed
WO-1997030969-A1 PHARMACEUTICAL AGENTS CONTAINING PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THE USE THEREOF IN TUMOUR THERAPY AND INTERVENTIONAL RADIOLOGY SCHERING AKTIENGESELLSCHAFT (DE) 1997-08-28 WO disclosed
EP-0252736-B1 PROCESS FOR PREPARING FLUORINE-CONTAINING CARBOXYLIC ACID ESTER SAGAMI CHEMICAL RESEARCH CENTER (JP) 1991-07-24 EP disclosed
US-4855487-A Process for preparing fluorine-containing carboxylic acid ester SAGAMI CHEMICAL RESEARCH CENTER (JP) 1989-08-08 US disclosed
EP-0252736-A2 Process for preparing fluorine-containing carboxylic acid ester SAGAMI CHEMICAL RESEARCH CENTER (JP) 1988-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050147563-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis FABP1, FLOT1, AFF1 LMNA 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.